Quidel Corporation Issues Clarification Regarding Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Reactivity Information to the QuickVue Influenza A+B Test Package Insert

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, issues clarification regarding the Special 510(k) clearance for an update to the Company’s QuickVue® Influenza A+B test package insert. A news wire agency released misleading information stating there is a new swine flu version of Quidel’s QuickVue Influenza A+B test and that FDA approved this new version. This statement is incorrect.